Pediatric drug development outlook promising, Tufts
An increase in resources dedicated to pediatric drug development is proving promising in the industry, according to a new analysis completed by the Tufts Center for the Study of Drug Development.
An increase in resources dedicated to pediatric drug development is proving promising in the industry, according to a new analysis completed by the Tufts Center for the Study of Drug Development.
Only one-third of manufacturing is currently conducted in-house, from development stages to after commercial launch, according a recent report.
Cellectar Biosciences has announced INC Research as its contract research organization (CRO) for the company’s Phase II trial of CLR 131 in hematologic malignancies.
Parexel has launched an Identification of Medicinal Products (IDMP)-focused solution to help biopharmaceutical companies meet impending regulatory requirements.